FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to basic research in the field of biomedical technologies and can be used to simulate an inflammatory response in mice. Mice are immunized with an oligonucleotide construct based on SB sequences: 5'-CCCCCGGGGGAACACAGGCAGGCAGGCAGGACCCCC CGGGGGAACGCCAACGCC-3'; BB: 5'-CCCCCGGGGGCCCCAGGGA GACCAAAAGCACCAGCCCCCGGGGGAACGCCAACGCC-3', obtained by synthesis of antisense sequences of oligonucleotides. On the first day, the first immunization of mice is carried out, the second immunization of mice is carried out on 14th day with the concentration of oligonucleotide structure 17–117 ng/mcl and molecular weight from 15,000 to 20,000 g/mol.
EFFECT: method provides creation of new, safe and effective platforms for production of vaccines capable of flexible change and adaptation to new subtypes of RNA viruses by immunizing mice with an oligonucleotide construct based on sequences obtained by synthesis of antisense oligonucleotide sequences.
1 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING OLIGONUCLEOTIDE SARS-Cov-2 VIRUS VACCINE | 2023 |
|
RU2824405C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| PIV5-BASED COVID-19 VACCINE | 2021 |
|
RU2838536C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
